

Supplemental Amendment
Serial No. 09/857,739
Page 3

Listing of the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

1. (Currently amended) An *in vitro* method for detecting a cancer-associated marker protein present in a bodily fluid of a mammal comprising:

(a) contacting a sample of bodily fluid from said mammal with antibodies directed against at least one epitope of said the marker protein; and

(b) detecting the presence of any complexes formed between said antibodies and the marker protein present in the sample;

wherein said the antibodies are mammalian autoantibodies to said the cancer-associated marker protein, which are derived from the same species as the mammal from which said the sample has been obtained, and

wherein detection of the complexes indicates the presence of the cancer-associated marker protein in the bodily fluid.

2. (Currently amended) The method of claim 1 wherein said the sample is from a mammal substantially asymptomatic for pre-neoplasia or cancer.

3. (Currently amended) The method of claim 1 wherein said the sample is from a mammal symptomatic for cancer.

4. (Currently amended) The method of claim 1 wherein said the sample is from a mammal that has received therapy for cancer.

5-51. (Canceled)

52. (Previously presented) The method of claim 1 wherein the mammal is a human and the autoantibodies are human autoantibodies.

Supplemental Amendment
Serial No. 09/857,739
Page 4

53. (Previously presented) The method of claim 1 wherein the bodily fluid is plasma, serum, whole blood, urine, feces, lymph, cerebrospinal fluid or nipple aspirate.

54. (Currently amended) The method of claim 1 wherein the cancer-associated marker protein is associated with ~~lymphomas, leukaemias,~~ breast cancers, colorectal cancers, lung cancers, pancreatic cancers, prostate cancers, cervical cancers, ovarian cancers, endometrial cancers or cancers of the skin.

55. (Currently amended) The method of claim 54 1 wherein the cancer-associated marker protein is a breast cancer associated marker protein.

56. (Currently amended) The method of claim 1 wherein the cancer-associated marker protein is a modified MUC1, BRCA1, p53, c-myc, c-erbB2 ~~e-erbP2~~ or Ras protein.

57. (Currently amended) The method of claim 55 wherein the cancer-associated marker protein is a modified MUC1, BRCA1, BRCA2, p53, c-myc, c-erbB2 ~~e-erbP2~~ or Ras protein associated with primary breast cancer.

58. (Currently amended) The method of claim 55 wherein the cancer-associated marker protein is a modified MUC1, BRCA1, BRCA2, p53, c-myc, c-erbB2 ~~e-erbP2~~ or Ras protein associated with advanced breast cancer.

59. (Previously presented) The method of claim 57 wherein the autoantibodies are obtainable from monocytes isolated from a patient with primary breast cancer.

Supplemental Amendment
Serial No. 09/857,739
Page 5

60. (Previously presented) The method of claim 58 wherein the autoantibodies are obtainable from monocytes isolated from a patient with advanced breast cancer.

61. (Previously presented) The method of claim 1 wherein the autoantibodies are produced by an immortalized cell or cell population.

62. (Previously presented) The method of claim 1 wherein the autoantibodies are polyclonal antibodies.

63. (Previously presented) The method of claim 1 wherein the autoantibodies are immobilized on a solid surface.

64. (Previously presented) The method of claim 63 wherein any complexes formed between the autoantibodies and any cancer-associated marker protein present in the sample are detected using secondary antibodies or autoantibodies specific for at least one epitope of said marker protein, the secondary autoantibodies carrying a detectable label.

65. (Previously presented) The method of claim 63 wherein in addition to the sample a labeled cancer-associated marker protein is added carrying at least one epitope recognized by the autoantibodies.

66. (Currently amended) ~~Use of the method of claim 1~~ An *in vitro* method for detecting a cancer-associated marker protein present in a bodily fluid of a mammal to screen for recurrence of cancer after a treatment, to monitor systemic therapies or to select therapies comprising:

Supplemental Amendment
Serial No. 09/857,739
Page 6

(a) contacting a sample of bodily fluid from said mammal with antibodies directed against at least one epitope of the marker protein, wherein the antibodies are mammalian autoantibodies to the cancer-associated marker protein and derived from the same species as the mammal from which the sample has been obtained; and

(b) detecting the presence of any complexes formed between the antibodies and the marker protein present in the sample;

wherein detection of the complexes indicates the presence of the cancer-associated marker protein in the bodily fluid.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.